Caspase-3, a key apoptotic protein, as a prognostic marker in gastric cancer after curative surgery
- 1 April 2018
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 52, 258-263
Abstract
Caspase-3 acts as a major executioner protein in proteolytic degradation during apoptosis. The role of Caspase-3 in gastric cancer remains controversial. A total of 366 gastric cancer patients who received curative surgery were enrolled. Caspase-3 expression in gastric tumors was examined by immunohistochemical staining. Correlations between Caspase-3 expression and the survival rates and between Caspase-3 expression and the clinicopathological parameters of the gastric cancer patients were analyzed. The 5-year overall survival rates of gastric cancer patients with and without Caspase-3 expression were 51.2% and 37.3%, respectively (P = 0.030). The 5-year disease-free survival rates of gastric cancer patients with and without Caspase-3 expression were 49.2% and 34.6%, respectively (P = 0.029). Analyses of the clinicopathological features showed that larger tumor size (P = 0.030), more advanced Borrmann type (P = 0.012), more aggressive stromal reaction (P = 0.001), higher classification using Ming's infiltrating histology type (P = 0.018), more lymph node involvement (P = 0.019), and more lymphovascular involvement (P = 0.045) were significantly correlated with a lack of Caspase-3 expression. The multivariate analysis showed that age (P = 0.001), Borrmann classification (P = 0.032), stromal reaction type (P = 0.018), TNM pathological T category (P = 0.002), TNM pathological N category (P < 0.001), and Caspase-3 expression (P = 0.041) were significantly correlated with the overall survival of gastric cancer patients. Caspase-3 expression in gastric cancer patients is related to favorable clinicopathological features and a positive prognosis after curative surgery. Caspase-3 may act as a tumor suppressor in human gastric cancer.Keywords
Funding Information
- Taipei Veterans General Hospital (V106C-083)
- Ministry of Science and Technology (MOST 105-2314-B-075-005-MY2)
This publication has 19 references indexed in Scilit:
- Japanese gastric cancer treatment guidelines 2014 (ver. 4)Gastric Cancer, 2016
- Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approachCell Death & Disease, 2016
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Targeting the XIAP/caspase-7 complex selectively kills caspase-3–deficient malignanciesJournal of Clinical Investigation, 2013
- Expression and prognostic significance of osteopontin and caspase‐3 in hepatocellular carcinoma patients after curative resectionCancer Science, 2010
- Evaluation of caspase-3 and caspase-8 deregulation in tongue squamous cell carcinoma, based on immunohistochemistry and computerised image analysisThe Journal of Laryngology & Otology, 2008
- Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancerInternational Journal of Colorectal Disease, 2007
- Nodal dissection for patients with gastric cancer: a randomised controlled trialThe Lancet Oncology, 2006
- Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistanceOncogene, 2002
- Gastric carcinoma:A pathobiological classificationCancer, 1977